Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
glioblastoma
Biotech
Imvax takes brain cancer therapy to FDA despite missing primary
Imvax shrugged off the failure to hit its primary endpoint, reporting evidence of improved overall survival and making a beeline for the FDA.
Nick Paul Taylor
Dec 2, 2025 8:00am
BioLineRx forges joint cancer venture with Norwegian biotech
Sep 29, 2025 11:22am
NCI axes funding for pediatric brain cancer trial consortium
Aug 26, 2025 6:50am
SandboxAQ, iOncologi partner to create brain cancer vaccine
Jul 16, 2025 10:58am
Alpheus nets $52M for ultrasound-activated brain tumor therapy
May 16, 2025 12:26pm
Telix shows 'promising’ 13-month OS in ph. 2 brain cancer study
Apr 16, 2025 6:30am
